Vertex's Sales Plunge 64% as It Refocuses Its Pipeline on Cystic Fibrosis Therapies

Kalydeco sales soar, but Vertex abandons its hepatitis C drug Incivek, causing revenue and EPS to tumble.

May 1, 2014 at 5:46PM

Large-cap biopharmaceutical company Vertex Pharmaceuticals (NASDAQ:VRTX) is right in the middle of a product transition from a dual focus on hepatitis C and cystic fibrosis to a full focus on cystic fibrosis – and its first-quarter results demonstrate those struggles.

For the quarter, Vertex reported a 64% decline in revenue, to $118.5 million, despite revenue from cystic fibrosis drug Kalydeco soaring 61%, to $99.5 million. Its huge revenue drop came from Vertex pulling away from marketing its hepatitis C therapy Incivek, which saw product sales fall to just $3.9 million. (Keep in mind this was the previous fastest-growing drug to ever reach $1 billion in sales.) Comparatively, Incivek produced $205.6 million in sales in the first-quarter last year.

The good news here is that focusing solely on cystic fibrosis dropped Vertex's operating expenses to $334.8 million from $766.7 million in the prior-year period, although research and development expenses rose 10%.

Vertex's adjusted bottom-line results reversed course from a $5.7 million profit, or $0.03 per share, in the year-ago period to a huge $151.4 million loss, or $0.65 per share. Vertex blamed the loss on reduced sales of Incivek and lower royalty revenue from Incivo. Vertex also ended the quarter with $1.32 billion in cash.

Looking ahead, Vertex is forecasting full-year revenue of $520 million-$550 million, excluding revenue from Incivek and its Incivo royalties, with Kalydeco revenue of $470 million-$500 million. Operating expenses are anticipated to be in the $890 million-$930 million range.

Subsequent to its earnings release, Vertex also announced that the addition of VX-661 to Kalydeco improves lung function in cystic fibrosis patients who are heterozygous to the F508del and G551D mutations in a phase 2 proof-of-concept study. Treatment involving this combo produced a mean within-group relative improvement in lung function of 7.3%.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information